Eligible patients for the NHS Pneumococcal Immunisation Programme

Catch Them. You Can.

Eligible patients for the NHS Pneumococcal Immunisation Programme

PNEUMOVAX® 23 (pneumococcal polysaccharide vaccine)
Prescribing Information [External link]

Pneumococcal disease poses a burden to the community all year round – not only in winter, unlike seasonal influenza.1

Certain patients are at increased risk of complications

Both at-risk individuals and over-65-year-olds have a higher risk of developing pneumococcal disease, longer duration of hospitalisation and/or higher rates of mortality.2-6

Patients with COPD
Patients with diabetes
People over 65 years old
Public health policy recommends PPV23 in patients with COPD and diabetes, as well as adults over 65, as part of the NHS Pneumococcal National Immunisation Programme in the UK* - reference 7

Order and start vaccinating today

Your patients may be unprotected against pneumococcal disease8

PPV coverage rate for patients - COPD 56.8% protected, 43.2% unprotected; diabetes 56.2% protected, 43.8% unprotected; over 65s 71.5% protected, 28.5% unprotected

Other clinical risk groups eligible for PPV237

  • Asplenia or dysfunction of the spleen
  • Diabetes requiring insulin or anti-diabetic medication
  • Chronic respiratory disease (chronic respiratory disease refers to chronic lower respiratory tract disease) including COPD
  • Immunosuppression
  • Chronic heart disease
  • Individuals with cochlear implants
  • Chronic kidney disease
  • Individuals with cerebrospinal fluid leaks
  • Chronic liver disease
  • Occupational risk

Please refer to the Green Book – Immunisation against infectious disease (Chapter 25)1, for a full list of children aged 2 years and over and adults, considered at risk.7

PPV23 can be administered at your clinic all year round
Order and start vaccinating today7,9

Check PPV23 stock status

Find further resources on the use of PPV23 in your eligible patients on our Resources page

*PNEUMOVAX® 23 (pneumococcal polysaccharide vaccine) is recommended for active immunisation against pneumococcal disease in children aged from 2 years, adolescents and adults.9

COPD = chronic obstructive pulmonary disease; PPV = pneumococcal polysaccharide vaccine.

References

  1. Torres A, et al. Thorax 2015;70(10):984–989.
  2. Martins M, et al. BMJ Open Diabetes Res Care. 2016;4:e000181.
  3. Falcone M, et al. Medicine 2016;95(5):e2531.
  4. Restrepo MI, et al. Tuberc Respir Dis. 2018;81:187–197.
  5. Dai RX, et al. BMC Pulm Med. 2018;18(1):12.
  6. Grant LR, et al. Expert Rev Vaccines. 2021;20(6):691–705.
  7. The Green Book – Immunisation against infectious disease (January 2020). Chapter 25 – Pneumococcal. Available at: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/857267/GB_Chapter_25_pneumococcal_January_2020.pdf.
  8. UK Health Security Agency. Pneumococcal Polysaccharide Vaccine (PPV) coverage report, England, April 2021 to March 2022. Available at: https://www.gov.uk/government/publications/pneumococcal-polysaccharide-vaccine-ppv-vaccine-coverage-estimates/pneumococcal-polysaccharide-vaccine-ppv-coverage-report-england-april-2021-to-march-2022.
  9. Pneumovax-23 Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/9692/smpc.

By clicking the links above you will leave the MSD Connect website and be taken to third-party websites

Supporting documentation

PNEUMOVAX® 23 (pneumococcal polysaccharide vaccine)
Prescribing Information

By clicking the link above you will leave the MSD Connect website and be taken to the emc PI portal website

GB-PNX-00320 | Date of Preparation: August 2023